- Home
- HDB vs SNY Comparison
HDB vs SNY Comparison
Compare HDB & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDB
- SNY
- Stock Information
- Founded
- HDB 1994
- SNY 1994
- Country
- HDB India
- SNY France
- Employees
- HDB N/A
- SNY N/A
- Industry
- HDB Commercial Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- HDB Finance
- SNY Health Care
- Exchange
- HDB Nasdaq
- SNY Nasdaq
- Market Cap
- HDB N/A
- SNY 144.8B
- IPO Year
- HDB N/A
- SNY N/A
- Fundamental
- Price
- HDB $66.44
- SNY $55.46
- Analyst Decision
- HDB Hold
- SNY Buy
- Analyst Count
- HDB 1
- SNY 2
- Target Price
- HDB N/A
- SNY $62.50
- AVG Volume (30 Days)
- HDB 2.7M
- SNY 2.9M
- Earning Date
- HDB 04-21-2025
- SNY 04-24-2025
- Dividend Yield
- HDB 1.95%
- SNY 3.96%
- EPS Growth
- HDB 1.99
- SNY 2.94
- EPS
- HDB 1.06
- SNY 4.60
- Revenue
- HDB $31,579,866,698.00
- SNY $45,849,466,833.00
- Revenue This Year
- HDB N/A
- SNY $6.91
- Revenue Next Year
- HDB $12.29
- SNY $6.60
- P/E Ratio
- HDB $20.12
- SNY $12.07
- Revenue Growth
- HDB 39.80
- SNY 7.73
- 52 Week Low
- HDB $54.99
- SNY $45.22
- 52 Week High
- HDB $68.50
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- HDB 71.72
- SNY 45.68
- Support Level
- HDB $60.03
- SNY $53.98
- Resistance Level
- HDB $67.12
- SNY $56.00
- Average True Range (ATR)
- HDB 0.84
- SNY 0.74
- MACD
- HDB 0.50
- SNY -0.52
- Stochastic Oscillator
- HDB 90.41
- SNY 28.52
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.